Recent chatter on X about Johnson & Johnson (JNJ) has been buzzing with reactions to the company's latest earnings report and raised 2024 guidance. Posts highlight a notable 6% stock price increase following the Q2 results, which surpassed expectations, sparking renewed interest in the healthcare giant. Many users are pointing to the firm's pipeline of new cancer drugs as a potential growth driver.
Additionally, discussions on X have noted analyst upgrades and raised price targets from several major financial institutions, reflecting confidence in JNJ's operational strength and market position. Some users have emphasized the stock's stability amid broader healthcare sector fluctuations, though others express a cautious, wait-and-see approach regarding long-term momentum. The conversation remains dynamic as investors weigh these positive developments against broader market trends.
Note: This discussion summary was generated from an AI condensation of post data.
Johnson & Johnson Congressional Stock Trading
Members of Congress have traded $JNJ stock 20 times in the past 6 months. Of those trades, 9 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE SCOTT FRANKLIN sold up to $50,000 on 06/16.
- REPRESENTATIVE PETE SESSIONS sold up to $50,000 on 06/12.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 06/10, 03/04 and 0 sales.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 4 times. They made 2 purchases worth up to $100,000 on 05/30, 03/31 and 2 sales worth up to $30,000 on 04/29, 01/24.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 3 times. They made 2 purchases worth up to $100,000 on 03/05, 02/24 and 1 sale worth up to $100,000 on 05/12.
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 05/05.
- REPRESENTATIVE BRUCE WESTERMAN has traded it 2 times. They made 1 purchase worth up to $15,000 on 03/03 and 1 sale worth up to $15,000 on 04/21.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 1 purchase worth up to $15,000 on 01/24 and 2 sales worth up to $30,000 on 04/09, 03/07.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $15,000 on 04/08.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 04/01.
- REPRESENTATIVE GEORGE WHITESIDES sold up to $250,000 on 03/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Johnson & Johnson Insider Trading Activity
Johnson & Johnson insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOHN C REED (EVP, Innovative Medicine, R&D) sold 19,137 shares for an estimated $3,129,829
- JOSEPH J WOLK (Exec VP, CFO) sold 13,015 shares for an estimated $2,002,878
- ROBERT J DECKER (VP Corporate Controller) sold 6,999 shares for an estimated $1,160,994
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) sold 403 shares for an estimated $62,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Johnson & Johnson Hedge Fund Activity
We have seen 1,783 institutional investors add shares of Johnson & Johnson stock to their portfolio, and 2,026 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 15,277,413 shares (+39.4%) to their portfolio in Q1 2025, for an estimated $2,533,606,171
- GAMMA INVESTING LLC removed 7,166,000 shares (-99.3%) from their portfolio in Q2 2025, for an estimated $1,094,606,500
- PRICE T ROWE ASSOCIATES INC /MD/ removed 6,177,098 shares (-37.9%) from their portfolio in Q1 2025, for an estimated $1,024,409,932
- ROBERT WOOD JOHNSON FOUNDATION removed 6,167,294 shares (-71.0%) from their portfolio in Q1 2025, for an estimated $1,022,784,036
- BANK OF AMERICA CORP /DE/ added 4,972,642 shares (+22.1%) to their portfolio in Q1 2025, for an estimated $824,662,949
- BANK OF NEW YORK MELLON CORP added 4,842,582 shares (+26.4%) to their portfolio in Q1 2025, for an estimated $803,093,798
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,354,793 shares (+493.7%) to their portfolio in Q1 2025, for an estimated $722,198,871
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Johnson & Johnson Government Contracts
We have seen $39,960,313 of award payments to $JNJ over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- 4565676752!5.5MM TI CANN SCREW + ST - 65MM: $558,058
- 4566846440!TRILEAP MODULAR 1ST MTP SYSTEM: $506,953
- 8510979866!OTHER MEDICAL: $399,070
- 4565921178!2.4MM VA-LCP DISTAL: $363,348
- 4565956035!CSS+ SMALL SET: $290,401
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Johnson & Johnson Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 07/17/2025
- UBS issued a "Buy" rating on 07/17/2025
- Raymond James issued a "Outperform" rating on 04/16/2025
- Goldman Sachs issued a "Buy" rating on 04/09/2025
To track analyst ratings and price targets for Johnson & Johnson, check out Quiver Quantitative's $JNJ forecast page.
Johnson & Johnson Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 9 analysts offer price targets for $JNJ in the last 6 months, with a median target of $175.0.
Here are some recent targets:
- Matt Miksic from Barclays set a target price of $176.0 on 07/17/2025
- Terence Flynn from Morgan Stanley set a target price of $176.0 on 07/17/2025
- Tim Anderson from B of A Securities set a target price of $175.0 on 07/17/2025
- Danielle Antalffy from UBS set a target price of $190.0 on 07/17/2025
- Vamil Divan from Guggenheim set a target price of $167.0 on 07/17/2025
- Shagun Singh from RBC Capital set a target price of $185.0 on 07/17/2025
- David Risinger from Leerink Partners set a target price of $153.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
